Brahma Capital is a private investment firm focused on investing in biotechnology, special situations and public markets. Founded in 2019 by Sundeep Agrawal, the firm seeks outsized returns by identifying transformative companies with proven management teams. The firm invests the personal capital of its Founder and co-invests with strategic capital partners.
Brahma Capital Outsized Returns
Our Metrics
15+ investments
Founded in 2019, we have made over 15 investments
1 sector expertise
Our investments are focused across biotech, public equities, and special situations
$10B+ value
Our portfolio has generated $10B+ in market value on the public markets
Select Investments
NASDAQ: VRNA
NASDAQ: PCVX
NASDAQ: RUM
NASDAQ: ERAS
NASDAQ: ABVX
NASDAQ: ERAS
NASDAQ: RCKT
NASDAQ: SPRY
NASDAQ: RVMD
NASDAQ: IMVT
NASDAQ: MRTX
Acquired by BMS for $5.8B in January 2024
NASDAQ: RUM
Featured News
Brahma Capital invests in the $278M PIPE for Caldera Therapeutics
Combined company to operate as Caldera Therapeutics, developing CLD-423, a potential firstin-class...
JULY 29, 2026
Brahma Capital invests in the $132M PIPE for Kira Pharmaceuticals
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes...
JULY 16, 2026
Brahma Capital Co-Leads $84M Financing for BlossomHill Therapeutics
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline...
DECEMBER 10, 2025
Merck to Acquire Verona Pharma for Approximately $10B
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio...